Who
Jason P. Rhodes
Director
Company insider
Files Form 4 as: Director, Dyne Therapeutics; Director, Generation Bio Co; Director, Replimune Group; Director and 10% owner, Disc Medicine; President, CFO and Treasurer, Epizyme.
In numbers
- Trades disclosed
- 402
- Buys
- 2
- Sells
- 65
- Bought
- $25.0M
- Sold
- $344.7M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 1 Jul 2013
- Last trade
- 14 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $34.0M1,359,674 at $25.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $12.0M478,377 at $25.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $8.1M322,465 at $25.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $34.0M1,359,674 at $25.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $12.0M478,377 at $25.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $8.1M322,465 at $25.00 | filing |
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $7.0M268,354 at $26.20 | filing |
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.5M94,415 at $26.20 | filing |
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.7M63,643 at $26.20 | filing |
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $7.0M268,354 at $26.20 | filing |
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.5M94,415 at $26.20 | filing |
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.7M63,643 at $26.20 | filing |
| 7 Jul 2026filed 8 Jul 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $118K5,000 at $23.61 | filing |
| 7 Jul 2026filed 8 Jul 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.9M124,379 at $23.17 | filing |
| 7 Jul 2026filed 8 Jul 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $699K29,587 at $23.62 | filing |
| 7 Jul 2026filed 8 Jul 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M62,543 at $23.17 | filing |
| 7 Jul 2026filed 8 Jul 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $351K14,844 at $23.62 | filing |
| 7 Jul 2026filed 8 Jul 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.1M49,193 at $23.17 | filing |
| 7 Jul 2026filed 8 Jul 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $276K11,665 at $23.62 | filing |
| 7 Jul 2026filed 8 Jul 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.9M124,379 at $23.17 | filing |
News
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)DYN · manilatimes.net · 22 Oct 2026
0 headlines in the last 90 days name Jason P. Rhodes; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.